



ASX Release

12 December 2024

Cleansing notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) Share Placement

Acrux Ltd (ASX:ACR) (**Company**) gives this notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Act**).

The Company refers to its announcement on 5 December 2024 regarding the successful conclusion of a share placement raising approximately \$2.65 million (before costs).

On 11 December 2024 the Company partially completed the share placement and issued 65,714,262 fully paid ordinary shares (**Shares**) to institutional and professional investors at an issue price of 3.5 cents per Share. Commitments are in hand for the full placement amount to be received.

The Company gives notice that:

- (1) the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- (2) this notice is being given under section 708A(5)(e) of the Act;
- (3) as at the date of this notice, it has complied with:
 - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (b) section 674 of the Act; and
- (4) as at the date of this notice, there is no information that is “excluded information” (as defined in sections 708A(7) and (8) of the Act) which is required to be set out in this notice under section 708A(6)(e) of the Act.

This announcement has been authorised for release to the ASX by the Board of Directors.

For more information, please contact:

Michael Kotsanis
CEO & Managing Director
E: michael.kotsanis@acrux.com.au

Joanna Johnson
CFO & Company Secretary
E: joanna.johnson@acrux.com.au

P: + 61 3 8379 0100

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux

encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit: www.acrux.com.au